BioMelbourne Network Progressing BioIndustry

• Home
• About Us
• Events
• Grants & Awards
• News & Opinion
• Membership
• VicBioPortal
• Resource Library
• Contact

14th April - Australian medical research and public health organisation, Burnet Institute has signed aAUD$5million agreement with GuoMinXinHe Investment Fund, Beijing to develop low-costdiagnostic tests to improve the health of millions of people in China and around the world. The agreement between the two organisations was officially signed in Shanghai today aspart of the Prime Minister’s Tra... read more…

7th April - ..Forum uniquely brings together leading family offices and their foundations seeking impact investment, grant-giving and philanthropy opportunities within health and life sciences..One of only two Australian companies participating Melbourne, Australia 7 April 2014: Australian Parkinson’s Disease technology company Global Kinetics Corporation (GKC) has been selected to present at ... read more…

21st March - CLOSING DATE: 29 May, 5.00 pm local time in Canberra Online nominations: http://www.industry.gov.au/scienceprizes The Prime Minister's Prizes for Science are Australia’s national annual awards for recognition of outstanding achievement in science and excellence in science education. Nominations are open to Australian citizens and Australian permanent residents.  The five awards a... read more…

13th March - Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is pleased to announce that ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in now approved by the Therapeutic Goods Administration (TGA) for the first-line treatment of metastatic pancreatic cancer. The TGA approved indication is: ABRAXANE, in combination with gemcitab... read more…

12th March - Victorian Coalition Government extends partnership with Massachusetts Life Sciences Center (MLSC) Coalition Government commits $1 million to second round of Building Global Bridges initiative Coalition Government supporting internationalisation of Victorian life sciences industry The Victorian Coalition Government has extended its partnership with renowned innovation invest... read more…

12th March - Victorian Coalition Government supporting new medtech program providing free mentoring Victorian medtech companies to benefit from world-leading expertise Coalition Government driving innovation and growth across the state’s life sciences sector Minister for Technology Gordon Rich-Phillips has announced the Victorian Coalition Government is supporting a new program that pr... read more…

4th March - • Appointment of industry leader to emerging company• Growing team to drive and fast-track global activities• Innovative telomerase technology set for roll out in US markets in 2014 Sienna Cancer Diagnostics has appointed Matthew Hoskin as Chief Operating Officer in a move which strengthens the company’s capacity as it progresses commercialisation of its innovative technology for ... read more…

3rd March - Applications are now open for the 2014 L’Oréal Australia & New Zealand For Women in Science Fellowships We’re offering three AU$25,000 Fellowships for outstanding young female scientists through the highly competitive For Women in Science Fellowship program. The Fellowships will be awarded to three Australian or New Zealand women who have shown scientific excellence in their career... read more…

3rd March - Australian drug delivery technology company Phosphagenics Limited (ASX:POH; OTCQX:PPGNY) has appointed biotech industry veterans Mr Lawrence Gozlan, Mr Nathan Drona and Dr Geert Cauwenbergh as non-executive directors, with Mr Gozlan assuming the role of Chairman of the Board on an interim basis.   Mr Stuart James, Dr Sandra Webb, Mr Don Clarke and Mr Jonathan Addison have retired fr... read more…

24th February - Melbourne, Australia, 24th February 2014- Cancer Therapeutics CRC (CTx) is pleased to announce that the Cooperative Research Centres (CRC) Program has agreed to continue their funding for a further six years. The application, submitted in June 2013, highlighted both the success of CTx since its formation in July 2007 as well as the plans to build on that success.  The focus of t... read more…

24th February -  Axiron® launched by Eli Lilly in Germany  Testosterone therapy market in Germany is the second largest outside the US Acrux (ASX: ACR) today confirmed that Axiron® has now launched in Germany for testosterone replacement therapy in men for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). Germany is the second largest testost... read more…

21st February - Dr Tania Obranovich has joined the Watermark Melbourne office as Special Counsel. Tania practices as both a patent attorney and solicitor, specialising exclusively in biotechnology. She brings to Watermark the experience obtained in pursuing molecular and cellular immunology research to the post-doctoral level, as well as 20 years experience as an attorney with another national... read more…

21st February - The Australian Government will create three new Cooperative Research Centres (CRCs) and extend four existing CRCs to drive research that will deliver practical benefits to industry and the community in fields including manufacturing, agriculture, health care and data security. Announcing almost $186 million in funding, Minister for Industry Ian Macfarlane said CRCs bring togeth... read more…

20th February - · World first offering of a telomerase-based cancer diagnostic for bladder cancer · Cost-effective non-invasive urine-based test for key biomarker · Bladder cancer the fifth most common cancer in USA, but most expensive to treat Melbourne-based biotech firm Sienna Cancer Diagnostics has been awarded a Federal Government grant to commercialise its innovative technology for us... read more…

6th February - As part of the Victorian International Engagement Strategy the Victorian Government has established the Hamer Scholarships, a language and cultural immersion program designed to build the Asia-engagement capabilities of Victorians and help strengthen cultural awareness between Victoria and Asia. The program provides scholarships for Victorians each year to undertake intensive la... read more…

5th February - • Phase 2 trial met its primary endpoint, reduced pain in postherpetic neuralgia (PHN) versus placebo• Significant patient response to EMA401 treatment and drop in pain intensity compared with placebo, meeting a key secondary endpoint • First published demonstration of the therapeutic potential of angiotensin II type 2 (AT2) receptor antagonists• EMA401 identified as a possible ... read more…

3rd February - Global business communications consultancy, College Group (including leading brands College Hill, The College, College Public Policy, Policy Action, Green Issues Communique, Stockheim Media and Instinctif) announces that it is today rebranding and unifying its business operations under one single brand – Instinctif Partners.  This move sees all its operations – 20 wholly owned of... read more…

28th January - • Hormone replacement therapy (HRT) a large and growing therapeutic segment• Opportunity for IDT to acquire a HRT product application in the mid stages of FDA review• Good fit to IDT facilities and capabilities• Attractive commercial terms IDT Australia Limited (ASX:IDT) has secured an exclusive option agreement with Perrigo Company plc (Perrigo) to evaluate an acquisition of P... read more…

21st January, 2014• Novartis has launcheda diclofenac formulation under the product name Voveran®TPM gel in the Indian market• Themis’ launch of its diclofenac product Instanac® TPM gel in the Indian market will occur imminently Drug delivery technology company Phosphagenics Limited (ASX:POH; OTCQX:PPGNY) advises that Novartis has launched a topical diclofenac gel that has been formulated with... read more…

18th January - • Study shows ABRAXANE plus gemcitabine combination therapy further extends overall survival benefit • First Phase III trial in metastatic pancreatic cancer to report three year survival rates1• New standard of care for patients with metastatic pancreatic cancer A leading breast cancer drug, ABRAXANE® (nanoparticle albumin-bound paclitaxel), has been shown to extend overall sur... read more…